$Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC$

Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC

Episodes

Specialty:

All

Year:

All

EP. 1: Continuum of Care for Metastatic CRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 2: Initiating Therapy for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 3: Second-Line Treatment for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 4: Later Lines of Therapy for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 5: CORRECT, RECOURSE, and ReDOS Trials in mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 6: Therapeutic Agents in Relapsed/Refractory mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 7: Sequencing in mCRC: Later-Line Therapies

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 8: Using I/O in MSI-H Tumors in mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 9: Role of I/O Combination Therapies in mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 10: Key Trials in mCRC: I/O Combination Therapies

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

EP. 11: Future Directions in Later Line Therapy for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL